Australia’s BANDIT (baricitinib in new onset type 1 diabetes trial) explained
Posted 12th August 2021
Lead scientists and clinicians from the research team explain the BANDIT (baricitinib in new onset type 1 diabetes) trial - what causes the disease and how they are hoping baricitinib may help newly-diagnosed people retain their insulin production for longer.
The trial is still open and people aged 10 - 30 who have been diagnosed with type 1 diabetes in the last 100 days are encouraged to apply. For more information, or to register, visit www.svi.edu.au/bandit Thank you to JDRF for funding this trial.